Early Metabolic Markers of the Development of Dysglycemia and Type 2 Diabetes and Their Physiological Significance
Metabolomic screening of fasting plasma from nondiabetic subjects identified α-hydroxybutyrate (α-HB) and linoleoyl-glycerophosphocholine (L-GPC) as joint markers of insulin resistance (IR) and glucose intolerance. To test the predictivity of α-HB and L-GPC for incident dysglycemia, α-HB and L-GPC m...
Saved in:
| Published in | Diabetes (New York, N.Y.) Vol. 62; no. 5; pp. 1730 - 1737 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Alexandria, VA
American Diabetes Association
01.05.2013
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0012-1797 1939-327X 1939-327X |
| DOI | 10.2337/db12-0707 |
Cover
| Abstract | Metabolomic screening of fasting plasma from nondiabetic subjects identified α-hydroxybutyrate (α-HB) and linoleoyl-glycerophosphocholine (L-GPC) as joint markers of insulin resistance (IR) and glucose intolerance. To test the predictivity of α-HB and L-GPC for incident dysglycemia, α-HB and L-GPC measurements were obtained in two observational cohorts, comprising 1,261 nondiabetic participants from the Relationship between Insulin Sensitivity and Cardiovascular Disease (RISC) study and 2,580 from the Botnia Prospective Study, with 3-year and 9.5-year follow-up data, respectively. In both cohorts, α-HB was a positive correlate and L-GPC a negative correlate of insulin sensitivity, with α-HB reciprocally related to indices of β-cell function derived from the oral glucose tolerance test (OGTT). In follow-up, α-HB was a positive predictor (adjusted odds ratios 1.25 [95% CI 1.00–1.60] and 1.26 [1.07–1.48], respectively, for each standard deviation of predictor), and L-GPC was a negative predictor (0.64 [0.48–0.85] and 0.67 [0.54–0.84]) of dysglycemia (RISC) or type 2 diabetes (Botnia), independent of familial diabetes, sex, age, BMI, and fasting glucose. Corresponding areas under the receiver operating characteristic curve were 0.791 (RISC) and 0.783 (Botnia), similar in accuracy when substituting α-HB and L-GPC with 2-h OGTT glucose concentrations. When their activity was examined, α-HB inhibited and L-GPC stimulated glucose-induced insulin release in INS-1e cells. α-HB and L-GPC are independent predictors of worsening glucose tolerance, physiologically consistent with a joint signature of IR and β-cell dysfunction. |
|---|---|
| AbstractList | Metabolomic screening of fasting plasma from nondiabetic subjects identified α-hydroxybutyrate (α-HB) and linoleoyl-glycerophosphocholine (L-GPC) as joint markers of insulin resistance (IR) and glucose intolerance. To test the predictivity of α-HB and L-GPC for incident dysglycemia, α-HB and L-GPC measurements were obtained in two observational cohorts, comprising 1,261 nondiabetic participants from the Relationship between Insulin Sensitivity and Cardiovascular Disease (RISC) study and 2,580 from the Botnia Prospective Study, with 3-year and 9.5-year follow-up data, respectively. In both cohorts, α-HB was a positive correlate and L-GPC a negative correlate of insulin sensitivity, with α-HB reciprocally related to indices of β-cell function derived from the oral glucose tolerance test (OGTT). In follow-up, α-HB was a positive predictor (adjusted odds ratios 1.25 [95% CI 1.00-1.60] and 1.26 [1.07-1.48], respectively, for each standard deviation of predictor), and L-GPC was a negative predictor (0.64 [0.48-0.85] and 0.67 [0.54-0.84]) of dysglycemia (RISC) or type 2 diabetes (Botnia), independent of familial diabetes, sex, age, BMI, and fasting glucose. Corresponding areas under the receiver operating characteristic curve were 0.791 (RISC) and 0.783 (Botnia), similar in accuracy when substituting α-HB and L-GPC with 2-h OGTT glucose concentrations. When their activity was examined, α-HB inhibited and L-GPC stimulated glucose-induced insulin release in INS-1e cells. α-HB and L-GPC are independent predictors of worsening glucose tolerance, physiologically consistent with a joint signature of IR and β-cell dysfunction.Metabolomic screening of fasting plasma from nondiabetic subjects identified α-hydroxybutyrate (α-HB) and linoleoyl-glycerophosphocholine (L-GPC) as joint markers of insulin resistance (IR) and glucose intolerance. To test the predictivity of α-HB and L-GPC for incident dysglycemia, α-HB and L-GPC measurements were obtained in two observational cohorts, comprising 1,261 nondiabetic participants from the Relationship between Insulin Sensitivity and Cardiovascular Disease (RISC) study and 2,580 from the Botnia Prospective Study, with 3-year and 9.5-year follow-up data, respectively. In both cohorts, α-HB was a positive correlate and L-GPC a negative correlate of insulin sensitivity, with α-HB reciprocally related to indices of β-cell function derived from the oral glucose tolerance test (OGTT). In follow-up, α-HB was a positive predictor (adjusted odds ratios 1.25 [95% CI 1.00-1.60] and 1.26 [1.07-1.48], respectively, for each standard deviation of predictor), and L-GPC was a negative predictor (0.64 [0.48-0.85] and 0.67 [0.54-0.84]) of dysglycemia (RISC) or type 2 diabetes (Botnia), independent of familial diabetes, sex, age, BMI, and fasting glucose. Corresponding areas under the receiver operating characteristic curve were 0.791 (RISC) and 0.783 (Botnia), similar in accuracy when substituting α-HB and L-GPC with 2-h OGTT glucose concentrations. When their activity was examined, α-HB inhibited and L-GPC stimulated glucose-induced insulin release in INS-1e cells. α-HB and L-GPC are independent predictors of worsening glucose tolerance, physiologically consistent with a joint signature of IR and β-cell dysfunction. Metabolomic screening of fasting plasma from nondiabetic subjects identified alpha-hydroxybutyrate (alpha-HB) and linoleoyl-glycerophosphocholine (L-GPC) as joint markers of insulin resistance (IR) and glucose intolerance. To test the predictivity of alpha-HB and L-GPC for incident dysglycemia, alpha-HB and L-GPC measurements were obtained in two observational cohorts, comprising 1,261 nondiabetic participants from the Relationship between Insulin Sensitivity and Cardiovascular Disease (RISC) study and 2,580 from the Botnia Prospective Study, with 3-year and 9.5-year follow-up data, respectively. In both cohorts, alpha-HB was a positive correlate and L-GPC a negative correlate of insulin sensitivity, with alpha-HB reciprocally related to indices of beta-cell function derived from the oral glucose tolerance test (OGTT). In follow-up, alpha-HB was a positive predictor (adjusted odds ratios 1.25 [95% CI 1.00-1.60] and 1.26 [1.07-1.48], respectively, for each standard deviation of predictor), and L-GPC was a negative predictor (0.64 [0.48-0.85] and 0.67 [0.54-0.84]) of dysglycemia (RISC) or type 2 diabetes (Botnia), independent of familial diabetes, sex, age, BMI, and fasting glucose. Corresponding areas under the receiver operating characteristic curve were 0.791 (RISC) and 0.783 (Botnia), similar in accuracy when substituting cc-JIB and L-GPC with 2-h OGTT glucose concentrations. When their activity was examined, alpha-JIB inhibited and L-GPC stimulated glucose-induced insulin release in INS-le cells. alpha-JIB and L-GPC are independent predictors of worsening glucose tolerance, physiologically consistent with a joint signature of IR and beta-cell dysfunction. Diabetes 62:1730-1737, 2013 Metabolomic screening of fasting plasma from nondiabetic subjects identified α-hydroxybutyrate (α-HB) and linoleoyl-glycerophosphocholine (L-GPC) as joint markers of insulin resistance (IR) and glucose intolerance. To test the predictivity of α-HB and L-GPC for incident dysglycemia, α-HB and L-GPC measurements were obtained in two observational cohorts, comprising 1,261 nondiabetic participants from the Relationship between Insulin Sensitivity and Cardiovascular Disease (RISC) study and 2,580 from the Botnia Prospective Study, with 3-year and 9.5-year follow-up data, respectively. In both cohorts, α-HB was a positive correlate and L-GPC a negative correlate of insulin sensitivity, with α-HB reciprocally related to indices of β-cell function derived from the oral glucose tolerance test (OGTT). In follow-up, α-HB was a positive predictor (adjusted odds ratios 1.25 [95% CI 1.00–1.60] and 1.26 [1.07–1.48], respectively, for each standard deviation of predictor), and L-GPC was a negative predictor (0.64 [0.48–0.85] and 0.67 [0.54–0.84]) of dysglycemia (RISC) or type 2 diabetes (Botnia), independent of familial diabetes, sex, age, BMI, and fasting glucose. Corresponding areas under the receiver operating characteristic curve were 0.791 (RISC) and 0.783 (Botnia), similar in accuracy when substituting α-HB and L-GPC with 2-h OGTT glucose concentrations. When their activity was examined, α-HB inhibited and L-GPC stimulated glucose-induced insulin release in INS-1e cells. α-HB and L-GPC are independent predictors of worsening glucose tolerance, physiologically consistent with a joint signature of IR and β-cell dysfunction. Metabolomic screening of fasting plasma from nondiabetic subjects identified [alpha]-hydroxybutyrate ([alpha]-HB) and linoleoylglycerophosphocholine (L-GPC) as joint markers of insulin resistance (IR) and glucose intolerance. To test the predictivity of [alpha]-I-IB and L-GPC for incident dysglycemia, [alpha]-HB and L-GPC measurements were obtained in two observational cohorts, comprising 1,261 nondiabetic participants from the Relationship between Insulin Sensitivity and Cardiovascular Disease (RISC) study and 2,580 from the Botnia Prospective Study, with 3-year and 9.5-year follow-up data, respectively. In both cohorts, [alpha]-HB was a positive correlate and L-GPC a negative correlate of insulin sensitivity, with ([alpha]-HB reciprocally related to indices of [beta]-cell function derived from the oral glucose tolerance test (OGTT). In follow-up, [alpha]-HB was a positive predictor (adjusted odds ratios 1.25 [95% CI 1.00-1.60] and 1.26 [1.07-1.48], respectively, for each standard deviation of predictor), and L-GPC was a negative predictor (0.64 [0.48-0.85] and 0.67 [0.54-0.84l) of dysglycemia (RISC) or type 2 diabetes (Botnia), independent of familial diabetes, sex, age, BMI, and fasting glucose. Corresponding areas under the receiver operating characteristic curve were 0.791 (RISC) and 0.783 (Botnia), similar in accuracy when substituting [alpha]-HB and L-GPC with 2-h OGTY glucose concentrations. When their activity was examined, [alpha]-HB inhibited and L-GPC stimulated glucose-induced insulin release in INS-le cells, [alpha]-HB and L-GPC are independent predictors of worsening glucose tolerance, physiologically consistent with a joint signature of IR and [beta]-cell dysfunction. Metabolomic screening of fasting plasma from nondiabetic subjects identified α-hydroxybutyrate (α-HB) and linoleoyl-glycerophosphocholine (L-GPC) as joint markers of insulin resistance (IR) and glucose intolerance. To test the predictivity of α-HB and L-GPC for incident dysglycemia, α-HB and L-GPC measurements were obtained in two observational cohorts, comprising 1,261 nondiabetic participants from the Relationship between Insulin Sensitivity and Cardiovascular Disease (RISC) study and 2,580 from the Botnia Prospective Study, with 3-year and 9.5-year follow-up data, respectively. In both cohorts, α-HB was a positive correlate and L-GPC a negative correlate of insulin sensitivity, with α-HB reciprocally related to indices of [beta]-cell function derived from the oral glucose tolerance test (OGTT). In follow-up, α-HB was a positive predictor (adjusted odds ratios 1.25 [95% CI 1.00-1.60] and 1.26 [1.07-1.48], respectively, for each standard deviation of predictor), and L-GPC was a negative predictor (0.64 [0.48-0.85] and 0.67 [0.54-0.84]) of dysglycemia (RISC) or type 2 diabetes (Botnia), independent of familial diabetes, sex, age, BMI, and fasting glucose. Corresponding areas under the receiver operating characteristic curve were 0.791 (RISC) and 0.783 (Botnia), similar in accuracy when substituting α-HB and L-GPC with 2-h OGTT glucose concentrations. When their activity was examined, α-HB inhibited and L-GPC stimulated glucose-induced insulin release in INS-1e cells. α-HB and L-GPC are independent predictors of worsening glucose tolerance, physiologically consistent with a joint signature of IR and [beta]-cell dysfunction. Metabolomic screening of fasting plasma from nondiabetic subjects identified α-hydroxybutyrate (α-HB) and linoleoylglycerophosphocholine (L-GPC) as joint markers of insulin resistance (IR) and glucose intolerance. To test the predictivity of α-I-IB and L-GPC for incident dysglycemia, α-HB and L-GPC measurements were obtained in two observational cohorts, comprising 1,261 nondiabetic participants from the Relationship between Insulin Sensitivity and Cardiovascular Disease (RISC) study and 2,580 from the Botnia Prospective Study, with 3-year and 9.5-year follow-up data, respectively. In both cohorts, α-HB was a positive correlate and L-GPC a negative correlate of insulin sensitivity, with (α-HB reciprocally related to indices of β-cell function derived from the oral glucose tolerance test (OGTT). In follow-up, α-HB was a positive predictor (adjusted odds ratios 1.25 [95% CI 1.00-1.60] and 1.26 [1.07-1.48], respectively, for each standard deviation of predictor), and L-GPC was a negative predictor (0.64 [0.48-0.85] and 0.67 [0.54-0.84l) of dysglycemia (RISC) or type 2 diabetes (Botnia), independent of familial diabetes, sex, age, BMI, and fasting glucose. Corresponding areas under the receiver operating characteristic curve were 0.791 (RISC) and 0.783 (Botnia), similar in accuracy when substituting α-HB and L-GPC with 2-h OGTY glucose concentrations. When their activity was examined, α-HB inhibited and L-GPC stimulated glucose-induced insulin release in INS-le cells, α-HB and L-GPC are independent predictors of worsening glucose tolerance, physiologically consistent with a joint signature of IR and β-cell dysfunction. |
| Audience | Professional |
| Author | Nannipieri, Monica Camastra, Stefania Mari, Andrea Groop, Leif Ferrannini, Ele Adamski, Jerzy Adam, Klaus-Peter Lyssenko, Valeriya Natali, Andrea Milburn, Michael V. Kastenmüller, Gabi Tuomi, Tiinamaija Gall, Walter E. |
| Author_xml | – sequence: 1 givenname: Ele surname: Ferrannini fullname: Ferrannini, Ele organization: Department of Internal Medicine, University of Pisa School of Medicine, Pisa, Italy – sequence: 2 givenname: Andrea surname: Natali fullname: Natali, Andrea organization: Department of Internal Medicine, University of Pisa School of Medicine, Pisa, Italy – sequence: 3 givenname: Stefania surname: Camastra fullname: Camastra, Stefania organization: Department of Internal Medicine, University of Pisa School of Medicine, Pisa, Italy – sequence: 4 givenname: Monica surname: Nannipieri fullname: Nannipieri, Monica organization: Department of Internal Medicine, University of Pisa School of Medicine, Pisa, Italy – sequence: 5 givenname: Andrea surname: Mari fullname: Mari, Andrea organization: National Research Council Institute of Biomedical Engineering, Padua, Italy – sequence: 6 givenname: Klaus-Peter surname: Adam fullname: Adam, Klaus-Peter organization: Metabolon, Inc., Durham, North Carolina – sequence: 7 givenname: Michael V. surname: Milburn fullname: Milburn, Michael V. organization: Metabolon, Inc., Durham, North Carolina – sequence: 8 givenname: Gabi surname: Kastenmüller fullname: Kastenmüller, Gabi organization: Institute of Bioinformatics and Systems Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany – sequence: 9 givenname: Jerzy surname: Adamski fullname: Adamski, Jerzy organization: Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany – sequence: 10 givenname: Tiinamaija surname: Tuomi fullname: Tuomi, Tiinamaija organization: Department of Medicine, Helsinki University Central Hospital, and Research Program of Molecular Medicine, University of Helsinki, Helsinki, Finland, Folkhalsan Research Centre, Helsinki, Finland – sequence: 11 givenname: Valeriya surname: Lyssenko fullname: Lyssenko, Valeriya organization: Department of Clinical Sciences, Diabetes and Endocrinology, Lund University, Malmö, Sweden – sequence: 12 givenname: Leif surname: Groop fullname: Groop, Leif organization: Department of Clinical Sciences, Diabetes and Endocrinology, Lund University, Malmö, Sweden – sequence: 13 givenname: Walter E. surname: Gall fullname: Gall, Walter E. organization: Metabolon, Inc., Durham, North Carolina |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27317777$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23160532$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9k01v1DAQhiNURD_gwB9AkRASHLb1x8aOL0hVWwpSqyKxB26W44yzLt54sbOF_ffMstsuCxXxIdbkmXfsyTuHxV4feyiKl5QcM87lSdtQNiKSyCfFAVVcjTiTX_eKA0IwTqWS-8VhzreEEIHrWbHPOBWk4uygSBcmhWV5DYNpYvC2vDbpG6RcRlcOUyjP4Q5CnM-gH1ah82XuwtLCzJvS9G05Wc6hZOW5Nw0MkNexKfhUfp4us48hdt6aUH7xXe8dbnsLz4unzoQMLzbvo2Ly4WJy9nF0dXP56ez0amQlIcNIiAYaWjniyNgSAVIaIRWvVaVqMDUxFRtbIThvQTEJzpiGSU6dg1o5RfhRYday-QfMF42eJz8zaamj8Xoe02CCTpDBJDvVYaEzaKSwA2bwsc-aNZY2NWu1UpLrsQOma1e12rSskU6O6wY7fVS8X9fA1Bm0FruUUHen1M6X3k91F-80F1wIUqPA241Ait8XkAc989lCCKaHuMia8rGgtJJKIPr6L_Q2LlKPHUSqkpQzRemW6kwA7XsXsa5diepTzuqKyXHFkBo9QnXQAx4SveU8hnf440d4XC06wT6a8G4nAZkBfg6dWeSs68ur_x1mw9oYAnSg0RNnN7v8qz-b_tDte1Mj8GYDmIzmcwld5_OWQ5dIfJA7WXM2xZwTOG398Pv34-180JTo1Xjp1Xjp1Xhtr_WQcS_6L_sL9VIiMg |
| CODEN | DIAEAZ |
| CitedBy_id | crossref_primary_10_3390_cells8030204 crossref_primary_10_1016_j_clnu_2021_03_014 crossref_primary_10_1007_s11306_019_1571_9 crossref_primary_10_3390_biomedicines12020363 crossref_primary_10_2337_dc15_2752 crossref_primary_10_1210_en_2013_1785 crossref_primary_10_1021_acs_jproteome_3c00797 crossref_primary_10_1152_physrev_00015_2017 crossref_primary_10_3389_fphar_2021_735410 crossref_primary_10_1161_CIRCRESAHA_120_315898 crossref_primary_10_3390_biom10071049 crossref_primary_10_1371_journal_pone_0148361 crossref_primary_10_1074_jbc_M113_476911 crossref_primary_10_3389_fendo_2022_935016 crossref_primary_10_1111_jns_12600 crossref_primary_10_1038_s41366_018_0189_8 crossref_primary_10_3390_nu15132942 crossref_primary_10_3390_jcm7120513 crossref_primary_10_1242_dmm_049157 crossref_primary_10_2337_db13_0605 crossref_primary_10_2337_dc19_2533 crossref_primary_10_1111_dom_14688 crossref_primary_10_3390_nu7115475 crossref_primary_10_3390_nu14040761 crossref_primary_10_1210_jc_2017_00475 crossref_primary_10_1016_j_envres_2018_09_034 crossref_primary_10_1007_s12170_015_0440_y crossref_primary_10_1016_j_jbc_2023_104764 crossref_primary_10_1007_s00125_022_05836_w crossref_primary_10_1016_j_cca_2023_117655 crossref_primary_10_1186_s13148_016_0177_6 crossref_primary_10_1021_acs_jproteome_7b00866 crossref_primary_10_3389_fendo_2023_1145111 crossref_primary_10_1007_s11306_017_1239_2 crossref_primary_10_1039_C5MB00158G crossref_primary_10_20960_revmedlab_00053 crossref_primary_10_3390_molecules27061889 crossref_primary_10_1080_10408398_2020_1851168 crossref_primary_10_3389_fmolb_2022_997436 crossref_primary_10_2337_dc21_1705 crossref_primary_10_1111_dom_12350 crossref_primary_10_1007_s11695_014_1377_9 crossref_primary_10_1152_ajpregu_00015_2014 crossref_primary_10_3389_fnut_2024_1364309 crossref_primary_10_4093_dmj_2017_41_6_466 crossref_primary_10_1007_s00125_015_3584_x crossref_primary_10_1074_jbc_REV120_012758 crossref_primary_10_3390_nu12051445 crossref_primary_10_1016_j_chmed_2018_03_004 crossref_primary_10_1093_jmcb_mjab051 crossref_primary_10_3390_metabo11080544 crossref_primary_10_1016_j_jprot_2014_03_025 crossref_primary_10_3945_ajcn_115_111872 crossref_primary_10_1161_JAHA_117_005705 crossref_primary_10_1210_jendso_bvac134 crossref_primary_10_1038_ijo_2017_124 crossref_primary_10_1039_C8FO02321B crossref_primary_10_3390_cimb43020039 crossref_primary_10_1055_s_0041_1726613 crossref_primary_10_3390_metabo13030451 crossref_primary_10_1016_j_celrep_2017_02_019 crossref_primary_10_3390_nu13030760 crossref_primary_10_1016_j_soard_2018_03_033 crossref_primary_10_1038_s41598_021_85684_7 crossref_primary_10_1016_j_ebiom_2021_103440 crossref_primary_10_2337_db13_0639 crossref_primary_10_1016_j_surg_2024_109055 crossref_primary_10_1111_joim_12859 crossref_primary_10_1016_j_ijcard_2016_07_214 crossref_primary_10_1007_s11892_022_01453_4 crossref_primary_10_1186_s12940_021_00810_2 crossref_primary_10_3389_fendo_2023_1237934 crossref_primary_10_1016_j_nbd_2024_106485 crossref_primary_10_1002_jcp_26518 crossref_primary_10_1016_S2213_8587_13_70175_X crossref_primary_10_1016_j_xgen_2023_100359 crossref_primary_10_3390_metabo12040357 crossref_primary_10_1080_10408363_2017_1414143 crossref_primary_10_1016_j_abb_2015_08_003 crossref_primary_10_2337_db14_0877 crossref_primary_10_1002_mrm_25716 crossref_primary_10_3390_metabo11120835 crossref_primary_10_1038_s42003_025_07549_3 crossref_primary_10_1016_j_ebiom_2021_103799 crossref_primary_10_1142_S0192415X21500865 crossref_primary_10_1007_s11892_022_01449_0 crossref_primary_10_1111_pedi_12323 crossref_primary_10_1093_aje_kwu143 crossref_primary_10_1016_j_envint_2016_10_012 crossref_primary_10_3389_fendo_2020_602477 crossref_primary_10_1007_s11306_023_01984_1 crossref_primary_10_3390_diagnostics12112881 crossref_primary_10_1038_s41598_020_78961_4 crossref_primary_10_1089_met_2024_0071 crossref_primary_10_1152_ajpendo_00001_2018 crossref_primary_10_1016_j_metabol_2016_12_018 crossref_primary_10_1038_nrendo_2015_142 crossref_primary_10_1371_journal_pone_0109772 crossref_primary_10_1007_s00125_019_05031_4 crossref_primary_10_1016_j_cmet_2017_04_011 crossref_primary_10_1073_pnas_1508425112 crossref_primary_10_1016_j_msard_2018_08_014 crossref_primary_10_1016_j_eng_2020_05_023 crossref_primary_10_1016_j_diabres_2018_03_045 crossref_primary_10_1016_j_jcte_2014_03_003 crossref_primary_10_1186_s12986_024_00807_x crossref_primary_10_1371_journal_pone_0097136 crossref_primary_10_1016_j_clnu_2019_04_035 crossref_primary_10_1093_nutrit_nuv010 crossref_primary_10_1016_j_jpba_2024_116018 crossref_primary_10_1007_s00125_016_4055_8 crossref_primary_10_1016_j_csbj_2022_10_030 crossref_primary_10_1038_s41598_018_19753_9 crossref_primary_10_1016_j_metabol_2016_06_007 crossref_primary_10_1016_j_metabol_2017_08_014 crossref_primary_10_1016_j_atherosclerosis_2019_04_225 crossref_primary_10_1073_pnas_1706096114 crossref_primary_10_1038_s41586_020_2337_2 crossref_primary_10_3389_fonc_2022_894891 crossref_primary_10_1007_s43393_023_00224_w crossref_primary_10_1016_j_csbj_2016_01_001 crossref_primary_10_3109_07853890_2015_1137630 crossref_primary_10_1038_s41467_022_29005_0 crossref_primary_10_1210_jc_2014_2080 crossref_primary_10_1007_s12020_018_1816_9 crossref_primary_10_1016_j_jpba_2017_02_056 crossref_primary_10_1152_ajpendo_00052_2016 crossref_primary_10_1007_s12020_014_0436_2 crossref_primary_10_1016_j_abb_2015_09_013 crossref_primary_10_1152_ajpregu_00325_2014 crossref_primary_10_1038_s41387_022_00213_3 crossref_primary_10_1021_acs_jproteome_7b00116 crossref_primary_10_3390_ijms23094534 crossref_primary_10_1021_acs_analchem_9b02909 crossref_primary_10_3390_ani14071045 crossref_primary_10_1016_j_jchromb_2016_10_025 crossref_primary_10_1007_s00592_024_02280_7 crossref_primary_10_1373_jalm_2016_021444 crossref_primary_10_1016_j_cca_2017_11_036 crossref_primary_10_1016_j_celrep_2015_09_054 crossref_primary_10_1186_s12916_022_02354_9 crossref_primary_10_3390_metabo12111036 crossref_primary_10_1016_j_lfs_2023_122137 crossref_primary_10_1111_dme_12352 crossref_primary_10_1530_JOE_14_0024 crossref_primary_10_1007_s00125_017_4325_0 crossref_primary_10_1111_nyas_13588 crossref_primary_10_1007_s11306_015_0802_y crossref_primary_10_1136_gutjnl_2019_318424 crossref_primary_10_1016_j_molmet_2016_08_011 crossref_primary_10_1007_s11357_023_00855_w crossref_primary_10_2337_db19_0131 crossref_primary_10_1210_jc_2019_01104 crossref_primary_10_1038_s41598_020_73384_7 crossref_primary_10_1007_s11306_023_02001_1 crossref_primary_10_1016_j_biocel_2017_10_011 crossref_primary_10_1210_en_2017_00148 crossref_primary_10_1002_oby_20868 crossref_primary_10_3389_fphar_2021_770240 crossref_primary_10_1007_s15034_016_0989_7 crossref_primary_10_1007_s40471_018_0140_5 crossref_primary_10_2116_analsci_18P281 crossref_primary_10_3389_fphar_2020_616157 crossref_primary_10_1007_s00125_017_4521_y crossref_primary_10_1016_j_lwt_2021_111224 crossref_primary_10_1038_s41598_018_21099_1 crossref_primary_10_3390_ijms24032603 crossref_primary_10_1042_BJ20141113 crossref_primary_10_3389_fendo_2022_1060309 crossref_primary_10_1007_s00125_015_3636_2 crossref_primary_10_1007_s00125_021_05618_w crossref_primary_10_1016_j_ecl_2021_05_011 crossref_primary_10_1371_journal_pone_0177738 crossref_primary_10_3390_molecules23071834 crossref_primary_10_14260_jemds_2021_376 crossref_primary_10_1007_s11011_021_00860_y crossref_primary_10_1111_dme_15064 crossref_primary_10_1089_dia_2024_0052 crossref_primary_10_1096_fj_201600927R crossref_primary_10_1177_193229681300700112 crossref_primary_10_1152_ajpendo_00464_2016 crossref_primary_10_3168_jds_2022_21938 crossref_primary_10_1136_bmjdrc_2014_000038 crossref_primary_10_1007_s00125_018_4573_7 crossref_primary_10_2337_db15_0661 crossref_primary_10_1016_j_biochi_2022_08_021 crossref_primary_10_1080_17446651_2018_1499466 crossref_primary_10_3390_biomedicines10020216 crossref_primary_10_1016_j_cca_2024_120023 crossref_primary_10_1161_CIRCGEN_118_002239 crossref_primary_10_1016_j_celrep_2016_09_005 crossref_primary_10_1177_1932296814553622 crossref_primary_10_2337_db15_1748 crossref_primary_10_33549_physiolres_935443 crossref_primary_10_1152_ajpendo_00287_2022 crossref_primary_10_1016_j_bbalip_2016_09_020 crossref_primary_10_1016_j_jhepr_2022_100477 crossref_primary_10_1089_met_2019_0047 crossref_primary_10_1139_apnm_2020_0171 crossref_primary_10_1152_ajpendo_00460_2014 crossref_primary_10_1093_advances_nmab073 crossref_primary_10_1371_journal_pone_0215918 crossref_primary_10_1093_ije_dyw145 crossref_primary_10_1373_clinchem_2014_228965 crossref_primary_10_1016_j_talanta_2018_10_064 crossref_primary_10_1007_s11892_017_0958_0 crossref_primary_10_2337_dc14_2033 crossref_primary_10_1038_s41598_017_08444_6 crossref_primary_10_1016_j_neubiorev_2014_12_017 crossref_primary_10_1161_CIRCULATIONAHA_116_024602 crossref_primary_10_3390_metabo12050431 crossref_primary_10_4239_wjd_v16_i1_100376 crossref_primary_10_1097_GME_0000000000000630 crossref_primary_10_1186_s40064_015_1304_0 crossref_primary_10_2337_db22_0033 crossref_primary_10_1210_jc_2018_01828 crossref_primary_10_1210_jc_2013_3596 crossref_primary_10_3390_biom13091424 crossref_primary_10_1186_s12889_023_17210_5 crossref_primary_10_3389_fmolb_2020_609806 crossref_primary_10_1016_j_foodhyd_2019_105582 crossref_primary_10_1155_2018_4207067 crossref_primary_10_1016_j_tem_2017_07_001 crossref_primary_10_2337_dc14_0090 crossref_primary_10_1007_s00125_013_3061_3 crossref_primary_10_2147_DMSO_S339604 crossref_primary_10_1093_ije_dyw033 crossref_primary_10_3390_nu13103322 crossref_primary_10_3389_fphys_2021_705588 crossref_primary_10_1016_j_celrep_2024_113960 crossref_primary_10_1186_s40795_022_00661_1 crossref_primary_10_1007_s11306_015_0890_8 crossref_primary_10_3390_cells10112832 crossref_primary_10_1096_fj_201802842RR crossref_primary_10_2337_dc15_2251 crossref_primary_10_3389_fnut_2023_1228703 crossref_primary_10_1111_joim_12117 crossref_primary_10_3945_ajcn_113_074070 crossref_primary_10_2337_db16_0315 crossref_primary_10_1111_cts_12131 crossref_primary_10_1002_cam4_7015 crossref_primary_10_1016_j_cca_2016_10_005 crossref_primary_10_2337_dc19_0100 crossref_primary_10_1161_HYPERTENSIONAHA_118_10919 crossref_primary_10_1007_s00394_019_01963_0 crossref_primary_10_1155_2017_5179271 crossref_primary_10_4331_wjbc_v6_i3_223 crossref_primary_10_1016_j_jacc_2021_02_070 crossref_primary_10_1016_j_cca_2017_01_002 crossref_primary_10_1016_j_molmet_2021_101355 crossref_primary_10_1038_s41598_019_45906_5 crossref_primary_10_1210_jc_2017_01057 crossref_primary_10_1007_s13410_018_0662_x crossref_primary_10_1016_S2213_8587_13_70143_8 crossref_primary_10_1038_s41598_022_19159_8 crossref_primary_10_2174_1389200221666200514081947 crossref_primary_10_3390_jcm7090235 crossref_primary_10_1007_s11306_017_1205_z crossref_primary_10_1038_s41598_019_43431_z crossref_primary_10_3390_nu14071454 crossref_primary_10_1155_2016_3467403 crossref_primary_10_1242_jeb_238915 crossref_primary_10_1002_hep_29465 crossref_primary_10_1016_j_plabm_2024_e00398 crossref_primary_10_3390_jcm9072257 crossref_primary_10_1007_s11306_016_1125_3 crossref_primary_10_1038_s41598_021_99147_6 crossref_primary_10_1210_jc_2015_2555 crossref_primary_10_3389_fphar_2016_00135 crossref_primary_10_4155_bio_15_244 crossref_primary_10_1016_j_jep_2022_115997 crossref_primary_10_1155_2016_3898502 crossref_primary_10_2174_1875318302111010017 crossref_primary_10_1038_s41598_019_42937_w crossref_primary_10_1152_ajpendo_00377_2017 |
| Cites_doi | 10.1093/oxfordjournals.aje.a010187 10.2337/diacare.23.3.295 10.1016/j.clnu.2011.02.009 10.1111/j.1753-0407.2009.00016.x 10.1093/oxfordjournals.aje.a116768 10.2337/db07-0887 10.1111/j.1476-5381.2011.01754.x 10.1016/j.cmet.2011.04.003 10.1016/j.bbrc.2008.11.122 10.1074/jbc.M109.024869 10.1007/s00125-011-2112-x 10.2337/diabetes.41.3.368 10.2337/diacare.22.9.1462 10.1002/dme.1996.13.s6.25 10.1056/NEJM196910092811503 10.1007/s00125-004-1335-5 10.1016/j.tem.2010.06.005 10.2337/db07-0111 10.1038/nm.2307 10.2337/diab.45.11.1585 10.2337/diab.46.6.1001 10.1152/ajpendo.00093.2002 10.1172/JCI116230 10.2337/dc08-2075 10.1056/NEJMoa0801869 10.1007/BF00280883 10.1007/s00125-004-1381-z 10.1111/j.1463-1326.2008.00946.x 10.3945/an.111.000737 10.1016/j.bbrc.2004.11.120 10.1210/en.2006-1608 10.1016/S0950-351X(05)80243-5 10.1016/j.freeradbiomed.2011.10.003 10.2337/db11-0425 10.2337/diabetes.52.2.463 10.1210/jc.2007-0334 10.1210/edrv.19.4.0336 10.1371/journal.pone.0015234 10.1007/s00726-011-1088-7 10.1371/journal.pone.0010883 |
| ContentType | Journal Article |
| Copyright | 2014 INIST-CNRS COPYRIGHT 2013 American Diabetes Association COPYRIGHT 2013 American Diabetes Association Copyright American Diabetes Association May 2013 2013 by the American Diabetes Association. 2013 |
| Copyright_xml | – notice: 2014 INIST-CNRS – notice: COPYRIGHT 2013 American Diabetes Association – notice: COPYRIGHT 2013 American Diabetes Association – notice: Copyright American Diabetes Association May 2013 – notice: 2013 by the American Diabetes Association. 2013 |
| CorporateAuthor | Lunds universitet Profile areas and other strong research environments Translational Muscle Research Department of Clinical Sciences, Malmö Lund University Translationell muskelforskning Strategiska forskningsområden (SFO) EpiHealth: Epidemiology for Health EXODIAB: Excellence of Diabetes Research in Sweden Faculty of Medicine Strategic research areas (SRA) Medicinska fakulteten Profilområden och andra starka forskningsmiljöer Institutionen för kliniska vetenskaper, Malmö |
| CorporateAuthor_xml | – name: Faculty of Medicine – name: Medicinska fakulteten – name: Strategiska forskningsområden (SFO) – name: Translationell muskelforskning – name: EpiHealth: Epidemiology for Health – name: Institutionen för kliniska vetenskaper, Malmö – name: Strategic research areas (SRA) – name: Lunds universitet – name: Translational Muscle Research – name: Profilområden och andra starka forskningsmiljöer – name: Lund University – name: EXODIAB: Excellence of Diabetes Research in Sweden – name: Profile areas and other strong research environments – name: Department of Clinical Sciences, Malmö |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 8GL 3V. 7RV 7X7 7XB 88E 88I 8AF 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K9- K9. KB0 LK8 M0R M0S M1P M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U S0X 7X8 5PM ADTPV AOWAS D95 |
| DOI | 10.2337/db12-0707 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: High School ProQuest Central (Corporate) ProQuest Nursing and Allied Health Journals - PSU access expires 11/30/25. Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database (ProQuest) ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library SciTech Premium Collection Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Medical Database Research Library (ProQuest) Science Database (ProQuest) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic SIRS Editorial MEDLINE - Academic PubMed Central (Full Participant titles) SwePub SwePub Articles SWEPUB Lunds universitet |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China ProQuest One Applied & Life Sciences Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Research Library ProQuest Public Health ProQuest Central Basic ProQuest Science Journals ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Research Library Prep MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1939-327X |
| EndPage | 1737 |
| ExternalDocumentID | oai_portal_research_lu_se_publications_2bc1b82d_9973_4fe2_8f5d_ad2b7f748b19 PMC3636608 2984468311 A328527452 23160532 27317777 10_2337_db12_0707 |
| Genre | Multicenter Study Journal Article |
| GeographicLocations | Italy Germany Finland |
| GeographicLocations_xml | – name: Finland – name: Germany – name: Italy |
| GroupedDBID | --- .55 .XZ 08P 0R~ 18M 29F 2WC 354 4.4 53G 5GY 5RE 5RS 5VS 6PF 7RV 7X7 88E 88I 8AF 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8GL 8R4 8R5 AAFWJ AAKAS AAQQT AAWTL AAYEP AAYOK AAYXX ABOCM ABUWG ACGFO ACGOD ACPRK ADBBV ADGHP ADZCM AEGXH AENEX AERZD AFKRA AHMBA AIAGR AIZAD ALIPV ALMA_UNASSIGNED_HOLDINGS AZQEC BAWUL BBNVY BCR BCU BEC BENPR BES BHPHI BKEYQ BKNYI BLC BPHCQ BTFSW BVXVI CCPQU CITATION CS3 DIK DU5 DWQXO E3Z EBS EDB EJD EMOBN EX3 F5P FRP FYUFA GICCO GNUQQ GUQSH GX1 H13 HCIFZ HMCUK HZ~ IAG IAO IEA IHR INH INR IOF IPO ITC K-O K2M K9- KQ8 L7B LK8 M0R M1P M2O M2P M2Q M5~ M7P NAPCQ O5R O5S O9- OB3 OHH OK1 OVD P2P PCD PEA PHGZM PHGZT PQQKQ PROAC PSQYO Q2X RHI RPM S0X SJFOW SJN SV3 TDI TEORI TR2 UKHRP VVN W8F WH7 WOQ WOW X7M YFH YHG YOC ZY1 ~KM .GJ 1CY 8F7 AAYJJ AFFNX AI. C1A H~9 IQODW J5H MVM N4W VH1 XOL YQJ ZGI ZXP CGR CUY CVF ECM EIF NPM PMFND 3V. 7XB 8FK K9. MBDVC PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS Q9U 7X8 PUEGO 5PM ADTPV AFLOD AOWAS D95 |
| ID | FETCH-LOGICAL-c700t-66beb15f0f04c06e77a679389598ea80a524c6633de927efaab2731ffe89f903 |
| IEDL.DBID | 7X7 |
| ISSN | 0012-1797 1939-327X |
| IngestDate | Sat Sep 27 03:11:22 EDT 2025 Thu Aug 21 13:55:58 EDT 2025 Sun Aug 24 03:18:27 EDT 2025 Fri Jul 25 19:34:15 EDT 2025 Tue Jun 17 20:55:03 EDT 2025 Thu Jun 12 23:30:07 EDT 2025 Tue Jun 10 20:38:12 EDT 2025 Fri Jun 27 03:39:44 EDT 2025 Tue Jun 10 19:53:20 EDT 2025 Thu Apr 03 06:56:58 EDT 2025 Wed Apr 02 07:27:13 EDT 2025 Thu Apr 24 23:10:33 EDT 2025 Tue Jul 01 03:04:09 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Endocrinopathy Type 2 diabetes Target tissue resistance Hyperglycemia Development Metabolic diseases Insulin resistance |
| Language | English |
| License | CC BY 4.0 Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c700t-66beb15f0f04c06e77a679389598ea80a524c6633de927efaab2731ffe89f903 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-General Information-1 content type line 14 ObjectType-Feature-3 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC3636608 |
| PMID | 23160532 |
| PQID | 1357132911 |
| PQPubID | 34443 |
| PageCount | 8 |
| ParticipantIDs | swepub_primary_oai_portal_research_lu_se_publications_2bc1b82d_9973_4fe2_8f5d_ad2b7f748b19 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3636608 proquest_miscellaneous_1346115796 proquest_journals_1357132911 gale_infotracmisc_A328527452 gale_infotracgeneralonefile_A328527452 gale_infotracacademiconefile_A328527452 gale_incontextgauss_8GL_A328527452 gale_incontextcollege_GICCO_A328527452 pubmed_primary_23160532 pascalfrancis_primary_27317777 crossref_citationtrail_10_2337_db12_0707 crossref_primary_10_2337_db12_0707 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-05-01 |
| PublicationDateYYYYMMDD | 2013-05-01 |
| PublicationDate_xml | – month: 05 year: 2013 text: 2013-05-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Alexandria, VA |
| PublicationPlace_xml | – name: Alexandria, VA – name: United States – name: New York |
| PublicationTitle | Diabetes (New York, N.Y.) |
| PublicationTitleAlternate | Diabetes |
| PublicationYear | 2013 |
| Publisher | American Diabetes Association |
| Publisher_xml | – name: American Diabetes Association |
| References | Huffman (2022031303173136700_B2) 2009; 32 Felig (2022031303173136700_B38) 1969; 281 Matthews (2022031303173136700_B20) 1985; 28 Porte (2022031303173136700_B22) 1996; 13 Yea (2022031303173136700_B28) 2009; 284 Adams (2022031303173136700_B30) 2011; 2 Kolak (2022031303173136700_B4) 2007; 56 Mari (2022031303173136700_B13) 2002; 283 Laakso (2022031303173136700_B16) 1993; 137 Mari (2022031303173136700_B19) 2008; 10 Stumvoll (2022031303173136700_B12) 2000; 23 Bonadonna (2022031303173136700_B36) 1993; 91 Fiehn (2022031303173136700_B31) 2010; 5 Wang (2022031303173136700_B5) 2011; 17 Van Cauter (2022031303173136700_B14) 1992; 41 Matsuda (2022031303173136700_B21) 1999; 22 Groop (2022031303173136700_B33) 1993; 7 2022031303173136700_B1 Adeva (2022031303173136700_B40) 2012; 43 Yea (2022031303173136700_B29) 2009; 378 Hanson (2022031303173136700_B17) 2000; 151 Perseghin (2022031303173136700_B32) 1997; 46 Cheng (2022031303173136700_B41) 2010; 21 Ferrannini (2022031303173136700_B9) 2007; 92 Gall (2022031303173136700_B6) 2010; 5 Lan (2022031303173136700_B27) 2012; 165 Shah (2022031303173136700_B3) 2011; 13 Rolo (2022031303173136700_B35) 2012; 52 Lyssenko (2022031303173136700_B7) 2008; 359 Ferrannini (2022031303173136700_B10) 2011; 54 Ferrannini (2022031303173136700_B15) 1998; 19 Hills (2022031303173136700_B8) 2004; 47 Hanley (2022031303173136700_B18) 2003; 52 Chu (2022031303173136700_B26) 2007; 148 Tessari (2022031303173136700_B39) 2011; 30 Groop (2022031303173136700_B11) 1996; 45 Ferrannini (2022031303173136700_B23) 2004; 47 Karpe (2022031303173136700_B34) 2011; 60 Pereira (2022031303173136700_B37) 2008; 57 Soga (2022031303173136700_B25) 2005; 326 Reaven (2022031303173136700_B24) 2009; 1 |
| References_xml | – volume: 151 start-page: 190 year: 2000 ident: 2022031303173136700_B17 article-title: Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies publication-title: Am J Epidemiol doi: 10.1093/oxfordjournals.aje.a010187 – volume: 23 start-page: 295 year: 2000 ident: 2022031303173136700_B12 article-title: Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity publication-title: Diabetes Care doi: 10.2337/diacare.23.3.295 – volume: 30 start-page: 267 year: 2011 ident: 2022031303173136700_B39 article-title: Insulin resistance of amino acid and protein metabolism in type 2 diabetes publication-title: Clin Nutr doi: 10.1016/j.clnu.2011.02.009 – volume: 1 start-page: 142 year: 2009 ident: 2022031303173136700_B24 article-title: Insulin secretory function in type 2 diabetes: does it matter how you measure it? publication-title: J Diabetes doi: 10.1111/j.1753-0407.2009.00016.x – volume: 137 start-page: 959 year: 1993 ident: 2022031303173136700_B16 article-title: How good a marker is insulin level for insulin resistance? publication-title: Am J Epidemiol doi: 10.1093/oxfordjournals.aje.a116768 – volume: 57 start-page: 56 year: 2008 ident: 2022031303173136700_B37 article-title: Insulin resistance of protein metabolism in type 2 diabetes publication-title: Diabetes doi: 10.2337/db07-0887 – volume: 165 start-page: 2799 year: 2012 ident: 2022031303173136700_B27 article-title: Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways publication-title: Br J Pharmacol doi: 10.1111/j.1476-5381.2011.01754.x – volume: 13 start-page: 491 year: 2011 ident: 2022031303173136700_B3 article-title: Branching out for detection of type 2 diabetes publication-title: Cell Metab doi: 10.1016/j.cmet.2011.04.003 – volume: 378 start-page: 783 year: 2009 ident: 2022031303173136700_B29 article-title: Lysophosphatidylserine regulates blood glucose by enhancing glucose transport in myotubes and adipocytes publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2008.11.122 – volume: 284 start-page: 33833 year: 2009 ident: 2022031303173136700_B28 article-title: Lysophosphatidylcholine activates adipocyte glucose uptake and lowers blood glucose levels in murine models of diabetes publication-title: J Biol Chem doi: 10.1074/jbc.M109.024869 – volume: 54 start-page: 1507 year: 2011 ident: 2022031303173136700_B10 article-title: Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study publication-title: Diabetologia doi: 10.1007/s00125-011-2112-x – ident: 2022031303173136700_B1 – volume: 41 start-page: 368 year: 1992 ident: 2022031303173136700_B14 article-title: Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance publication-title: Diabetes doi: 10.2337/diabetes.41.3.368 – volume: 22 start-page: 1462 year: 1999 ident: 2022031303173136700_B21 article-title: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp publication-title: Diabetes Care doi: 10.2337/diacare.22.9.1462 – volume: 13 start-page: S25 year: 1996 ident: 2022031303173136700_B22 article-title: Normal physiology and phenotypic characterization of beta-cell function in subjects at risk for non-insulin-dependent diabetes mellitus publication-title: Diabet Med doi: 10.1002/dme.1996.13.s6.25 – volume: 281 start-page: 811 year: 1969 ident: 2022031303173136700_B38 article-title: Plasma amino acid levels and insulin secretion in obesity publication-title: N Engl J Med doi: 10.1056/NEJM196910092811503 – volume: 47 start-page: 566 year: 2004 ident: 2022031303173136700_B8 article-title: The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives publication-title: Diabetologia doi: 10.1007/s00125-004-1335-5 – volume: 21 start-page: 589 year: 2010 ident: 2022031303173136700_B41 article-title: Insulin signaling meets mitochondria in metabolism publication-title: Trends Endocrinol Metab doi: 10.1016/j.tem.2010.06.005 – volume: 56 start-page: 1960 year: 2007 ident: 2022031303173136700_B4 article-title: Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity publication-title: Diabetes doi: 10.2337/db07-0111 – volume: 17 start-page: 448 year: 2011 ident: 2022031303173136700_B5 article-title: Metabolite profiles and the risk of developing diabetes publication-title: Nat Med doi: 10.1038/nm.2307 – volume: 45 start-page: 1585 year: 1996 ident: 2022031303173136700_B11 article-title: Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects publication-title: Diabetes doi: 10.2337/diab.45.11.1585 – volume: 46 start-page: 1001 year: 1997 ident: 2022031303173136700_B32 article-title: Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study publication-title: Diabetes doi: 10.2337/diab.46.6.1001 – volume: 283 start-page: E1159 year: 2002 ident: 2022031303173136700_B13 article-title: Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects publication-title: Am J Physiol Endocrinol Metab doi: 10.1152/ajpendo.00093.2002 – volume: 91 start-page: 514 year: 1993 ident: 2022031303173136700_B36 article-title: Effect of insulin on system A amino acid transport in human skeletal muscle publication-title: J Clin Invest doi: 10.1172/JCI116230 – volume: 32 start-page: 1678 year: 2009 ident: 2022031303173136700_B2 article-title: Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women publication-title: Diabetes Care doi: 10.2337/dc08-2075 – volume: 359 start-page: 2220 year: 2008 ident: 2022031303173136700_B7 article-title: Clinical risk factors, DNA variants, and the development of type 2 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa0801869 – volume: 28 start-page: 412 year: 1985 ident: 2022031303173136700_B20 article-title: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man publication-title: Diabetologia doi: 10.1007/BF00280883 – volume: 47 start-page: 943 year: 2004 ident: 2022031303173136700_B23 article-title: Beta cell function and its relation to insulin action in humans: a critical appraisal publication-title: Diabetologia doi: 10.1007/s00125-004-1381-z – volume: 10 start-page: 77 year: 2008 ident: 2022031303173136700_B19 article-title: Beta-cell function assessment from modelling of oral tests: an effective approach publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2008.00946.x – volume: 2 start-page: 445 year: 2011 ident: 2022031303173136700_B30 article-title: Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state publication-title: Adv Nutr doi: 10.3945/an.111.000737 – volume: 326 start-page: 744 year: 2005 ident: 2022031303173136700_B25 article-title: Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2004.11.120 – volume: 148 start-page: 2601 year: 2007 ident: 2022031303173136700_B26 article-title: A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release publication-title: Endocrinology doi: 10.1210/en.2006-1608 – volume: 7 start-page: 1007 year: 1993 ident: 2022031303173136700_B33 article-title: Insulin action and substrate competition publication-title: Baillieres Clin Endocrinol Metab doi: 10.1016/S0950-351X(05)80243-5 – volume: 52 start-page: 59 year: 2012 ident: 2022031303173136700_B35 article-title: Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2011.10.003 – volume: 60 start-page: 2441 year: 2011 ident: 2022031303173136700_B34 article-title: Fatty acids, obesity, and insulin resistance: time for a reevaluation publication-title: Diabetes doi: 10.2337/db11-0425 – volume: 52 start-page: 463 year: 2003 ident: 2022031303173136700_B18 article-title: Prediction of type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study publication-title: Diabetes doi: 10.2337/diabetes.52.2.463 – volume: 92 start-page: 2885 year: 2007 ident: 2022031303173136700_B9 article-title: Insulin resistance, insulin response, and obesity as indicators of metabolic risk publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2007-0334 – volume: 19 start-page: 477 year: 1998 ident: 2022031303173136700_B15 article-title: Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects publication-title: Endocr Rev doi: 10.1210/edrv.19.4.0336 – volume: 5 start-page: e15234 year: 2010 ident: 2022031303173136700_B31 article-title: Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women publication-title: PLoS ONE doi: 10.1371/journal.pone.0015234 – volume: 43 start-page: 171 year: 2012 ident: 2022031303173136700_B40 article-title: Insulin resistance and the metabolism of branched-chain amino acids in humans publication-title: Amino Acids doi: 10.1007/s00726-011-1088-7 – volume: 5 start-page: e10883 year: 2010 ident: 2022031303173136700_B6 article-title: alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population publication-title: PLoS ONE doi: 10.1371/journal.pone.0010883 |
| SSID | ssj0006060 |
| Score | 2.5598588 |
| Snippet | Metabolomic screening of fasting plasma from nondiabetic subjects identified α-hydroxybutyrate (α-HB) and linoleoyl-glycerophosphocholine (L-GPC) as joint... Metabolomic screening of fasting plasma from nondiabetic subjects identified [alpha]-hydroxybutyrate ([alpha]-HB) and linoleoylglycerophosphocholine (L-GPC) as... Metabolomic screening of fasting plasma from nondiabetic subjects identified α-hydroxybutyrate (α-HB) and linoleoylglycerophosphocholine (L-GPC) as joint... Metabolomic screening of fasting plasma from nondiabetic subjects identified alpha-hydroxybutyrate (alpha-HB) and linoleoyl-glycerophosphocholine (L-GPC) as... |
| SourceID | swepub pubmedcentral proquest gale pubmed pascalfrancis crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1730 |
| SubjectTerms | Adult Animals Biological and medical sciences Biological markers Biomarkers Biomarkers - blood Cardiovascular disease Cell Line Clinical Medicine Cohort Studies Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - metabolism Diabetes Mellitus, Type 2 - physiopathology Diabetes. Impaired glucose tolerance Diagnosis Early Diagnosis Endocrine pancreas. Apud cells (diseases) Endocrinology and Diabetes Endocrinopathies Endokrinologi och diabetes Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Follow-Up Studies Genetic aspects Glucose Glucose intolerance Glucose Metabolism Disorders - blood Glucose Metabolism Disorders - diagnosis Glucose Metabolism Disorders - metabolism Glucose Metabolism Disorders - physiopathology Humans Hydroxybutyrates - blood Hydroxybutyrates - metabolism Insulin - metabolism Insulin Resistance Insulin Secretion Insulin-Secreting Cells - metabolism Klinisk medicin Male Medical and Health Sciences Medical sciences Medicin och hälsovetenskap Metabolism Metabolites Middle Aged Original Research Phosphatidylcholines - blood Phosphatidylcholines - metabolism Physiological aspects Physiology Plasma Prospective Studies Rats ROC Curve Womens health |
| Title | Early Metabolic Markers of the Development of Dysglycemia and Type 2 Diabetes and Their Physiological Significance |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/23160532 https://www.proquest.com/docview/1357132911 https://www.proquest.com/docview/1346115796 https://pubmed.ncbi.nlm.nih.gov/PMC3636608 |
| Volume | 62 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1db9MwFLVgkxASQnyOwKgMQoOXaLGd-OMJjbIxITYQDKnixXIcu6tU0rK0D_v3-CZu14iKPvQhPoli-_rm2j4-F6E3VpSVJ9KlprBZmlOvUqkqmlrihbGSWeZblu85P_2Zfx4Vo7jg1kRa5conto66mllYIz8krBCQFJ2Q9_M_KWSNgt3VmELjNtolIRKB1A1itJ5wZSE4746gEAoynKJTFqKMicOqBEqCgCyyG9-j6JXvzU0TWsh3qS22xZ7_Uih7QqPtx-nkAbofo0p81JnBQ3TL1Y_QnbO4b_4YXbU6xvjMLUKfTycWwxGdEPjhmcchAsQb1CG49PG6GU-vrfs9MdjUFYbJKqY4smea7hrsMOCWQLryn_jHZFwD9Qgs6Qm6ODm-GJ6mMdtCakWWLVLOy-C3C5_5LLcZd0IYHgavVIWSzsjMFDS3IT5hlVNUOG9MGUIf4r2TyquMPUU79ax2zxAOmFIaRbwyee5zWgojQPhN-RCdKG4S9G7V5NpGJXJIiDHVYUYCvaOhdzT0ToJer6HzTn5jG-gA-k2DnEUNfBnbrbnoUL3hV33EqCzC5Lug4Wl94Ngsm0bLT196oLcR5GfhrayJ5xRC3UAqq4c86CHHnVD4NuB-DxhGsO0VD3oGt64ptK8Iv3D_ygJ1dDGNvhkQCXq1LoZHA22udrMlYHIOakqKJ2ivM9ibhzPCIS1IgkTPlNcAEB7vl9STy1aAnHHGeSYT9Ksz-v4t7bRRR62qSz1d6sbp-cYitKalJaWklVZKMJ17R7X0RaVNFWzFi1yWRD3_f51foLu0TUwC1NN9tLO4WrqXITxclIPWB4R_OSQDtPvh-Pzb90G7ivcXlaZoqA |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGkAAJIb4JjGEQDF6iJc6H7QeEpo3RsXY80EkVL5bj2F2lkpalFeofxf_IXZJ2jah4Wx7jX6w4dznf2effEfLW8Cx3obC-Tkzgx8xJX8ic-SZ0XBsRmchVWb5naec8_jpIBlvkz_IsDKZVLm1iZajzicE18v0wSjgWRQ_DT9NfPlaNwt3VZQmNWi1O7eI3hGzlx5MjkO87xo4_9w87flNVwDc8CGZ-mmZgnxIXuCA2QWo51ykoqZCJFFaLQCcsNjAPR7mVjFundQZTfOicFdLJIIJub5CbMe4wwu_DB6v4LoBYoD7xEjJk_eQ1kRGLIr6fZ5gBwbFo7dr010wCd6e6BIG4upLGJlf334zNFq9pNRce3yf3GieWHtRa94Bs2eIhudVrtukfkcuKNpn27AxUbDwyFE8EgZ9JJ46Cw0nXMpXw1tGiHI4Xxv4caaqLnGJsTBltknXK-h5uaNAqX3Vprun30bDATCdU3Mekfx1ieEK2i0lhnxEKmExoGTqp49jFLOOaI8-cdOAMyVR75MPykyvTEJ9j_Y2xggAIpaNQOgql45E3K-i0ZvvYBNpDuSlkzygwPcfUSzwKhnf4TR1ETCQQ6ycMemsDh3pelkp86bZA7xuQm8BbGd0ci4CxITNXC7nXQg5rXvJNwJ0WEAyGaTXvthRuNVL8vhwueH6pgaqxaKW6-v888nrVjF1jll5hJ3PExCmSN8nUI09rhb3qPApTrELiEd5S5RUAec7bLcXoouI7j9IoTQPhkR-10rcfqaJU1VBjXajxXJVWTdfWvBXLTJgJlispeaRiZ5kSLsmVzkFXHI9FFsrn_x_zK3K70-91Vffk7PQFucOqmiiY9bpDtmeXc_sSPNNZtlvZA0rUNdufv2F-oUQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGJk1ICHGnMIZBMHiJmjgX2w8TGruwsQsTDGnixXIcu6tU0rK0QvuJ_CvOSdyuERVv62PyxapzTs7FPv4OIW8MzwsXCRvo1IRBwpwMhCxYYCLHtRGxiV1d5XuS7X9PPp-n50vkz_QsDJZVTm1ibaiLocE18m4UpxybokdR1_myiNOdvQ-jXwF2kMKd1mk7De3bLBSbNd2YP-RxaK9-QzpXbR7sgOzfMra3e7a9H_iOA4HhYTgOsiwH25W60IWJCTPLuc5AgYVMpbBahDpliQEfHRdWMm6d1jm4_8g5K6STYQzD3iIrHJw-5IErH3dPTr_O3AJkCs15mIghJyhvaI5YHPNukWN9BMeWtnPO0buIOyNdgbhc02djUSD8bz1ni_W09pR798hdH-LSrUYn75MlWz4gq8d-E_8huaxJlemxHYMCDvqG4nkhiELp0FEIR-lcHRNe2rmqeoMrY3_2NdVlQTFzpoz6Up6quYbbHbSuZp0ac_qt3yuxDgrV-hE5uwlBPCbL5bC0TwkFTC60jJzUSeISlnPNUS2kg1BJZrpD3k9fuTKeFh27cwwUpEcoHYXSUSidDnk9g44aLpBFoA2Um0JujRK11DQLQAqmt_1FbcVMpIwnKYPR2sCenlSVEp-OWqB3HuSG8K-M9ocmYG7I29VCbrSQvYa1fBFwrQUEc2Jat9dbCjebKb5fDj94fqqBytu7Sl1_nR3yanYbh8YavtIOJ4hJMqR2klmHPGkU9nrwOMqwR0mH8JYqzwDIgt6-U_Yvajb0OIuzLBQd8qNR-vYjdQ6rPHHWhRpMVGXVaG5FXLHcRLlghYKPNlaJs0wJlxZKF6Arjicij-Sz_8_5JVkFW6SODk4On5PbrG6YgiWxa2R5fDmxLyBsHefr3iBQom7YBP0FuyOsHw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Early+Metabolic+Markers+of+the+Development+of+Dysglycemia+and+Type+2+Diabetes+and+Their+Physiological+Significance&rft.jtitle=Diabetes+%28New+York%2C+N.Y.%29&rft.au=Ferrannini%2C+Ele&rft.au=Natali%2C+Andrea&rft.au=Camastra%2C+Stefania&rft.au=Nannipieri%2C+Monica&rft.date=2013-05-01&rft.issn=1939-327X&rft.volume=62&rft.issue=5&rft.spage=1730&rft_id=info:doi/10.2337%2Fdb12-0707&rft.externalDocID=oai_portal_research_lu_se_publications_2bc1b82d_9973_4fe2_8f5d_ad2b7f748b19 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-1797&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-1797&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-1797&client=summon |